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Abstract 
Master thesis, Sahlgrenska academy, pneumonia among children less <5 Years in Cameroon 
following introduction of a 13-valent pneumococcal conjugate vaccine, Björn Wallén, 2014, 
Gothenburg, Sweden. 
Introduction Pneumonia is the largest killer in children under 5 years worldwide. In 
Cameroon it accounts for 18% of deaths in children < 5. Immunization is the most effective 
way to prevent pneumonia. Several studies show good effect with Pneumococcal Conjugate 
Vaccines (PCV). In Cameroon the PCV-13 vaccine was launched 2013-07. No evaluation has 
been done in Cameroon about all-cause pneumonia incidence after introduction of the 
vaccine. 
Aim The aim of the study was to see if the number of pneumonia cases decreased after 
launching the PCV13-programme? Are there changes in severity and mortality after 
immunization? Have the rates of invasive pneumococcal disease (IPD) declined?   
Method It was a retrospective study conducted at Buea and Limbe Regional Hospital during 
two months in autumn 2013. Cases were collected from 2009-06 to 2013-10. Inclusion criteria 
were having a pneumonia diagnosis and being 1 month - 5 years old. The study time was 
divided into one period before introduction of the PCV-13 vaccine program, and one period 
after the introduction.  
Results No change in number of cases, no positive effect on proportion of severe cases, and 
no decline in mortality were observed after vaccine introduction. More boys than girls were 
affected by pneumonia. There was a seasonal variation with negative correlation between 
rainfall and number of pneumonia cases. 
Discussion Reasons for the negative results remain unclear. Herd effects also take time to 
develop. Supposedly, Cameroon has a high percentage of non-vaccine serotypes? Do other 
factors, such as rainfall contribute to the result? 
Conclusions It is too early to conclude no vaccine effect for children in the region. More 
studies are needed. Finally, knowledge about serotype distribution among disease-causing 
pneumococci in the area is needed. 
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Introduction 
Global situation of pneumonia 
There are approximately 120 million episodes of pneumonia in children younger than 5 years 
every year(1), and pneumonia is the leading cause of death for children <5 worldwide(1-3), 
with an estimated 1.3 million deaths every year - more than AIDS, malaria and tuberculosis 
together(2).  The majority of deaths due to pneumonia occur in low-income countries in 
Africa and Southeast Asia(1). Pneumonia can be caused by virus, bacteria as well as fungi. 
Streptococcus pneumoniae is the most common cause of pneumonia in children worldwide. 
Case fatality rates for children under 5 years of age and especially those under two years of 
age may be as high as 20% for pneumonia in developing countries(4).  
In year 2000 following the millennium summits of the United Nations, eight international 
millennium development goals were established (MDG). The fourth millennium goal is about 
reducing child mortality by 2/3 from 1990 till 2015. As pneumonia alone stands for more 
deaths in young children than any other illnesses, controlling pneumonia is of crucial 
importance in achieving millennium goal nr 4(5). There are several factors contributing to 
pneumonia. In order to greatly reduce the number of episodes, a battery of interventions is 
needed. The Global Alliance for Vaccines and Immunization (GAVI) lists five interventions 
that have the most impact in reducing the burden of the disease that causes around one fifth of 
deaths worldwide(6).  
These are: 
 Immunization against whooping cough (pertussis), measles, Haemophilus influenza 
type b (HiB) and pneumococci;  
 Exclusive breastfeeding for 6 months and continued breastfeeding complemented by 
nutritious solid food up to age 2;  
 Safe drinking water, sanitation and hand washing facilities; 
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 Improved cooking stoves to reduce indoor air pollution; 
 Treatment, including amoxicillin dispersible tablets and access to oxygen.  
Of these five interventions, the WHO states that immunization is the most important and 
effective way to prevent pneumonia(2).  
Several studies from South Africa (7), United States (8-10), Italy(11, 12)
 
and from the 
Gambia (13) have shown that pneumococcal conjugate vaccines (PCV) are quite effective 
against childhood invasive pneumococcal disease (IPD) and clinical (or radiologically 
confirmed) pneumonia. In the randomized, placebo-controlled, double-blind Gambia study, 
the efficacy of the vaccine was 77% against IPD caused by vaccine serotypes and 50 % 
against IPD caused by all serotypes. In the same study, efficacy was 16% against mortality 
(13). In the WHO bulletin, volume 86, the authors estimate that the 13-valent vaccine may 
prevent 30-50% of radiologically and lethal pneumonia(14).  
In the two studies from Italy, the number of children hospitalized with all-cause pneumonia in 
the age group 0-2 years, decreased with 19% respectively 15% the year after introduction of 
the PCV-7 vaccine(11, 12).  
In a vast multidisciplinary group with support from GAVI Alliance and the Bill & Melinda 
Gates Foundation, the impact of immunization was estimated in 73 countries. Immunization 
with pneumococcal conjugate vaccine was estimated to avert 26 percent of the estimated, 
under-five pneumonia and meningitis deaths(15). 
 
Etiology and pathophysiology  
Pneumonia is defined pathologically as acute inflammatory consolidation of alveoli or 
infiltration of the interstitial tissue with inflammatory cells or a combination of both(16). 
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Often, the smaller bronchi and bronchioles are also affected as the infection usually originates 
from the upper respiratory tract.  
Pneumonia can be classified in different ways: 
 According to localization as in segmental pneumonia, lobar pneumonia or interstitial 
pneumonia 
 As cause of disease, for example aspiration pneumonia,  
 Due to causing agents such as Streptococcus pneumoniae, Haemophilus influenzae, 
Chlamydophila pneumoniae  
 
The most common bacterial agent of pneumonia in children is Streptococcus pneumoniae(17). 
More than 90 different serotypes of the Streptococcus pneumoniae are known(4).   
Carriage of Streptococcus pneumoniae in the nasopharynx is common. In pre-school children, 
carriage rates may be as high as 30-70 %(18). This does not necessarily lead to pneumococcal 
disease or pneumonia. However, people with immunodeficiency, people of old age and 
particularly infants are at greater risk(18, 19). In infants, pneumococcal pneumonia most 
commonly derives from the upper respiratory tract, with inflammatory secretion from the 
airways which later causes bronchial obstruction(16). When the bronchi are affected the 
infection spreads to include the alveoli that become packed with inflammatory exudate and 
involved parts of the lung become consolidated. Without treatment, infection may spread to 
involve lung lobes(19). 
Pneumococcal conjugate vaccines  
In the 1980s, polysaccharide vaccines were released on the market. These vaccines have 
capsular polysaccharides from 23 different pneumococcal serotypes. Polysaccharides induce a 
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B-cell dependent immune response (20). However, polysaccharide vaccines are not suitable 
for children under 2 years of age because of children’s immature immune system(21). Young 
children simply don´t have the same ability to produce antibodies against polysaccharides 
(20). The last decade’s pneumococcal conjugate vaccines have been developed and 7, 9 and 
10-valent pneumococcal vaccines have reached the market and have been implemented in 
immunization programs over the world (20). The advantage is that they are suitable and 
immunogenic for children below two years of age, unlike the pneumococcal polysaccharide 
vaccine (4, 18, 20, 21). Pneumococcal conjugate vaccines are made of polysaccharides from 
the capsule which are conjugated to a carrier protein, thereby making it possible for a T-cell 
dependent immune response to take place:  a B-cell binds the vaccine, type 2 helper T-cells 
interact with the B-cell-complex; then, antibody isotype switching, affinity maturation and 
production of memory B-cells follows (20). The newest of the PCV-vaccines is the 13-valent 
vaccine that is now being used also in Cameroon. It may protect against severe disease caused 
by the 13 different serotypes which are represented in the vaccine(15, 22). Unfortunately the 
PCV-13 vaccine does not have effect on non-vaccine serotypes or other pathogens(15). 
 
Diagnostics 
Pneumonia can present a variety of different symptoms such as difficult breathing, cough, 
fever, abdominal pain, headache, chills, grunting, convulsion and vomiting(3). Not only the 
symptoms vary, there are also different diagnostic criteria for pneumonia internationally (23). 
Diagnostic guidelines are also much dependent on site and medical facilities (23, 24). 
Microbiological methods and especially, chest x-ray has in many guidelines been “golden 
standard” for diagnosing pneumonia (3, 24). Though, for example in UK and US x-ray is not 
recommended in “non-hospital-settings”(24). To facilitate for health personnel, and 
particularly in low-income countries, in 1991 the WHO set up a model with guidelines to 
diagnose pneumonia and categorize it according to severity, based only on clinical symptoms 
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(see Table 1). This model is now integrated in the IMCI (Integrated Management of 
Childhood Illness)(3).  
 
  
Table 1. Pneumonia –WHO-definition with level of severity. 
Non-Severe Severe Very Severe 
Cough or difficult breathing 
and tachypnea 
 
None of the signs of severe 
or very 
Severe pneumonia. 
 
Other signs of pneumonia 
may be present: 
crackles, reduced breath 
sounds, or an 
area of bronchial breathing. 
Cough or difficult breathing 
plus at least one of the 
following signs: 
 
Lower chest wall indrawing 
 
Nasal flaring 
 
Grunting (in young infants). 
 
No signs of very severe 
pneumonia 
Cough or difficult breathing 
plus at least one of the 
following: 
 
Central cyanosis, 
Inability to breastfeed 
Or drink, or vomiting 
everything 
Convulsions, lethargy or 
unconsciousness 
 
Severe respiratory distress 
 
To our knowledge, there are no diagnostic guidelines for pneumonia in Cameroon.  
Cameroon 
Public spending in the health sector in Cameroon is low. With only 1.5 % of GDP few 
countries in Africa allocate less money for health care than Cameroon. The average public 
spending as percentage of the GDP for the other sub-Saharan countries is almost twice as 
high(25). 
There has been only small progress in the general health situation in Cameroon since 1990. 
Life expectancy has even fallen with two years. Maternal mortality is higher than the average 
for Sub-Saharan Africa, with 0.7 % case fatality rate for each pregnancy(25). Cameroon is far 
from achieving millennium goal 4; 12.2 % of all children die before reaching the age of 5 
years. From 1990 to 2010 child mortality reduced with only 12%, to be compared with 38% 
in average for the other sub-Saharan countries(25).  
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In Cameroon, malaria, pneumonia and diarrhea are the major causes of death in children. 18% 
of deaths among children < 5 are due to pneumonia(25, 26).  
Study Area 
Buea is the administrative centre of the South West region in Cameroon with a population of 
138 801(27). It is situated on the foot of Mount Cameroon close to 1000 meter above sea 
level, some 70 km west of economic capital of Douala, and only 20 km from the Atlantic 
Ocean. Buea is extremely humid with an yearly average rainfall of 3500 mm(28), and situated 
in the very proximity to the rainforest. There are two seasons: the rain season that stretches 
from May till September and the dry season that continues from late November to March. In-
between the seasons are the transition periods. With numerous eruptions from the still active 
volcano of Mount Cameroon, the soil is highly fertile. The country´s second largest employer, 
CDC (Cameroon development cooperation), have large plantations of banana, rubber, and 
palm oil in the region. The Tole Tea estate is another big employer. The city also comprises 
one of only two Anglophone Universities in the Country. The Buea area is best described as a 
semi-urban area, moderately rich for Cameroon standards with a population of farmers, 
students and administrative personnel working for the government.   
Study Setting  
The study was performed at the pediatric clinic in Buea Regional Hospital (BRH) and later 
also extended to include the pediatric clinic in Limbe Regional Hospital. Both of them are 
public hospitals. 
Buea Regional Hospital comprises thirteen different services, administration, pediatrics, 
surgery, maternity, operating theatre, x-ray, laboratory, dental, diabetes unit, tuberculosis unit, 
eye unit, family planning, outpatient, HIV / AIDS unit and the male and female medical units.  
Limbe Regional Hospital comprises services for radiology, surgery, dental surgery, 
gynecology and obstetrics, ophthalmology, pediatrics, maternity and general medicine.  
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Pediatric wards in Buea and Limbe. 
The ward is divided into two rooms with 8 beds in each room and the nursing unit situated in 
between the two. In-patients are children aged 0-14 years. Only one pediatrician is working in 
the Buea ward. Outside of office hours, a doctor is on call at the hospital. Every day there are 
also three nurses and one head nurse working the day shift and two nurses working the long 
evening/night shift. The pediatric department in Limbe comprises 10 beds.  
The maternity ward and the pediatrics are equipped with two incubators. There is oxygen 
treatment available. Blood pressure arm cuffs for children under 12 years of age were not 
present. There was no pulsoxymeter.   
 
Health system and fees 
Patients pay themselves for healthcare. For example, if attending medical care patients pay a 
consultation fee upon arrival at the hospital. To consult a general practioner in Buea, the fee is 
600-1500 CFA (8-20 SEK) depending on daytime/nighttime/week-end. To consult a 
specialist, the fee is from 2500 (35 SEK) CFA and upwards. In-patients then pay bed fee 500 
CFA (7 SEK) per night at the hospital, but has to bring their own sheets and food. 
Additionally, all medications, laboratory investigations, x-rays (chest x-ray 4-5000 CFA), 
surgery etc. the patients pay themselves. For a child with a pneumonia diagnosis, staying 2-3 
days at the hospital with standard investigations, the total cost for the parents is around 10000 
CFA (130 SEK).  These fees should be put in comparison with a normal monthly income 
(hospital nurse in Buea) of around 100.000 CFA (1300 SEK).  
 
Immunization 
Cameroon has an on-going vaccination program which includes immunization with BCG, 
DTP, Hep B, HiB, PCV-13, poliomyelitis, measles and yellow fever. Additionally vitamin A 
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is administered together with the vaccines. Vaccination is free; in some health centers parents 
pay only a small administrative fee for their children (100 CFA = 1.4 SEK).   
In July 2011 the PCV-13 vaccine was launched on a national basis. It is administered in three 
doses; at 6, 10 and 14 weeks of age.  
Little is known about the epidemiology of causative agents for pneumonia in Cameroon 
before introduction of the PCV-13 vaccine. However, among the invasive infections causing 
acute bacterial meningitis, two studies from Cameroon shows that 56.2 respectively 57.1 % of 
all cases were due to Streptococcus pneumoniae(29, 30).  
There are major regional differences in vaccine coverage in Cameroon. In the South-West, 
where Buea and Limbe are situated, 75.2 % of the population had a full immunization in 
2011, compared to only 30.9 % in the Extreme North(25). In the South West in 2013, two 
years after the introduction of the PCV-13 vaccine, an estimated 82 % of children up to two 
year old had received all three doses of the vaccine. In 2012 and the later part of 2011, 
coverage was 77% and 14% respectively(27). 
 
Figure 1. PCV-13 coverage in children <2 in the South-West region(27).  
 
 
82 
18  
PCV-13 coverage in the South-West region (%) 
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Treatment Guidelines Pneumonia 
There were standardized guidelines for treating pneumonia posted in the wall of the pediatric 
clinic in Buea. These were: 
1. Oxygen 
2. Antibiotic therapy 
In child 2 months – 3 years.  
 Amoxicillin – clavulanic acid 80-100 mg/kg/24 h. 
              (in 3 doses iv). 
In child 3 years and above  
 Ceftriaxone 50-75 mg/kg/24 h 
(in 1 dose iv or im) 
OR 
 Ampicillin or amoxicillin 150mg/kg/24 h. 
(in 3-4 doses iv or im). 
3. Antipyretics 
 Aspirin (in 3-4 doses iv, im or per os) 
 Paracetamol  (in 3-4 doses iv or per os) 
4. Cough syrups 
 Mucolytics  -  acetylcystein 
 Expectorants  -  carboncystein 
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Aim 
To our knowledge, no investigation about the epidemiology of childhood pneumonia in 
Cameroon has been performed after introduction of the PCV-13 vaccine. The aim of this 
study is to investigate the epidemiology of childhood pneumonia and to examine early effects 
of the PCV13-vaccine in Buea, Cameroon:   
 Has the number of confirmed pneumonia cases decreased after launching the PCV13-
programme?  
 Are there any early changes in mortality and severity when comparing the periods 
before and after immunization? 
 Have the rates of invasive pneumococcal infections among children under five 
declined after immunization?   
 
Method 
Study population and data collection 
The design was a retrospective hospital-based study at The Buea Regional Hospital (BRH). 
Limbe Regional Hospital was later also to become included in the study. At both hospitals all 
cases of pneumonia under 5 years of age, from June 2009 to October 2013, were identified 
through the admission book in the pediatric unit. Inclusion criteria was being between 1 
month and 5 years of age and having a pneumonia diagnosis in the admission book. 
Altogether 333 cases were included. 
The study period was divided into two periods of 26.5 months each; a “before period” June 
2009 to August 15 2011 and an “after period” August 15 2011 to October 2013. The vaccine 
was introduced July 2011 and the reason for setting the break point six weeks later, at 15
th
 of 
August 2011 is that children receive their first dose at the age of 6 weeks. 
15 
 
In Buea, the admission book held brief information about age, weight, gender, symptoms, 
investigations, concomitant diseases, treatment, no of days stayed at the hospital and case 
fatality. After identifying pneumonia cases that met the inclusion criteria, information was 
then obtained from the patients’ medical files stored in the archive. After going through four 
entire months of medical records, we learned that the medical files contained very little, or no 
additional information, compared to the admission book. All medical records were therefore 
not further investigated and focus was instead put on collecting a larger number of cases, why 
the study was extended to also include Limbe Regional Hospital. 
In Limbe Regional Hospital, the admission book comprised the same information as in Buea 
except that information about symptoms, investigations and treatment were missing.  
Classification 
All 205 cases in Buea Hospital were classified according to level of severity. As tachypnea is 
one of the clinical markers for non-severe pneumonia and as there was no information about 
respiratory rate, all cases that did not have any of the symptoms indicating severe or very 
severe pneumonia were automatically diagnosed as non-severe pneumonia. As there was only 
brief information about symptoms in the admission book, all cases that had any of the WHO-
symptoms severe- or very severe pneumonia were merged into one and classified as severe 
pneumonia. No classification according to level of severity was made for the Limbe Hospital 
cases due to the lack of information of symptoms.  
Statistical methods 
The raw data was analyzed using IBM SPSS Statistics version 21. The correlation between 
gender and other variables were assessed using the crosstabs. P-values were obtained using 
Fisher’s exact test. Descriptive statistics and frequencies were used to construct the tables 
presenting the results. To make the graphs Microsoft Excel 2010 was used. The significance 
cut off was set to p-value < 0.05.  
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Ethical considerations 
Ethical clearance was obtained from the Ministry of Public Health, in the Regional Delegation 
of the South West Region, Cameroon. Copies of the authorization to collect research data 
were given to the General Supervisor of the Buea Regional Hospital and to the Director of the 
Limbe Regional Hospital, and thereafter also stamped and approved. The study did not 
interfere with the care or treatment of the children in the pediatric unit during the time of the 
study. All cases and all medical information have been treated anonymously. 
 
Results 
Of all the cases 4 were excluded due to lack of information about gender,  and 11 were 
excluded because they were younger than 1 month. Remaining were 205 cases that met the 
inclusion criteria in Buea and another 128 cases in Limbe. Altogether 333 cases were included 
in the study. Mean age was 22,0 months. There was no information about vaccination status 
for each individual case; ; nevertheless vaccine coverage was reported to be 82 % in South-
West region in June 2013. Distribution of cases according to gender and fatality before and 
after vaccination is shown in table 2. 
Table 2. Distribution of cases before and after vaccine introduction.    
 No of cases Boys  Girls Fatal cases 
Before  167 92 75 2 
After 166 98 68 6 
Total 333 190 143 8 
 
When comparing the periods before and after the beginning of PCV13-vaccination, no 
decrease in the no of cases was seen. In both the before and the after period, there were more 
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boys than girls diagnosed with pneumonia. The distribution of concomitant diseases is shown 
in table 3 
Table 3. Concomitant diseases 
Concomitant diseases (N =333) % 
Malaria 29.8 
Gastroenteritis 6.0 
Malnutrition 2.1 
Rhinopharyngitis 1.8 
HIV 0.6 
Tuberculosis 0.6 
 
One third of all the pneumonia cases also suffered from malaria. The proportion of severe 
cases did not change after vaccination, p = 0,551 NS, (see figure 2).  Girls had severe 
pneumonia to a higher extent than boys; 38,9% compared to 27,0 %,  p = 0,073 NS, (see 
figure 3).  
Figure 2. Classification according to severity before and after introduction of the vaccine. 
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Figure 3.  Severity related to gender
 
We separated the children aged 1-24 months from the bigger < 5 age group and analyzed it 
separately. In this age group the number of pneumonia cases in Buea and Limbe rose from 
101 to 114 in the 1-24 months age group after vaccine introduction.  
Fatal cases 
The case fatality rose from 2 cases to 6 cases after vaccine introduction, p = 0.174 NS. 
Case fatality related to gender 
Of the 8 fatal cases that occurred during the study period, four were boys and four were girls.  
Invasive pneumococcal disease 
It was not possible to answer the third aim about rate of invasive pneumococcal disease. 
There was simply no information about IPD as blood cultures were not performed in Buea or 
Limbe regional hospital.  
Seasonal variation 
There was a seasonal variation over the 53 months that the study was conducted (see Figure 
4). We then calculated the monthly average of pneumonia cases over the study period (see 
Figure 4) and found out that from November to February was the highest number of 
pneumonia cases and from June to September we found the lowest monthly average of 
61% 
39% 
63% 
27% 
0%
10%
20%
30%
40%
50%
60%
70%
Non-Severe Severe
Girl
Boy
19 
 
pneumonia cases (see Figure 5). These months correlates very well with the dry season and 
the wet season respectively. A comparison was thus made between the average monthly 
precipitation and the monthly average of pneumonia cases (see figure 6). It appeared to be a 
negative correlation between rainfall and number of pneumonia cases. In the four driest 
months of the year put together, November - February, the average rainfall was 269 mm and 
the monthly average of pneumonia cases 36, 75. In the four wettest months, June - September 
put together, the average rainfall was 2505 mm and the monthly average of pneumonia cases 
only 17. That makes a 20-fold increase in rainfall and half the incidence in number of 
pneumonia cases during the wet season compared to the dry season.  
 
Figure 4. Seasonal variation on number of cases.   
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Figure 5. Monthly distribution of pneumonia cases over “peak months” and “bottom 
months”. 
 
 
 
Figure 6. Seasonal variation and correlation between average rainfall and average number of 
pneumonia cases 
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Oxygen treatment was used in 18 of the 205 (8,8 %) cases in Buea. The most common 
antibiotic treatment was the third generation cephalosporin Ceftriaxone (or equivalent 
generics) in combination with Gentamycin, followed by Ceftriaxone as single treatment. In 
45, 4 % of the cases, gentamycin were used despite the fact that it was not included in the 
treatment guidelines (See Table 4 and Treatment Guidelines).  
 
Table 4. Antibiotic treatments given. 
Antiobiotic treatment N (%) 
Third generation cephalosporin + Gentamycin 69 (33,5) 
Third generation cephalosporin 63 (30,6) 
Ampicillin + Gentamycin 16 (7,8) 
No antibiotics 13 (6,3) 
Ampicillin or Amoxicillin 12 (5,8) 
Ampicillin + clavulanic acid 8 (3,9) 
Ampicillin + third generation cephalosporin 8 (3,9) 
Ampicillin + third generation cephalosporin + Gentamycin 8 (3,9) 
Other 8 (3,9) 
Total 205 (100%) 
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Discussion 
Contrary to results from studies from England, Italy, US, South Africa and the Gambia, there 
was no change in the number of cases, level of severity or mortality in our study after 
introduction of the PCV-13 vaccine (7-13). What this stands for is not evident. Perhaps, we 
set the breakpoint too early after vaccine introduction. Herd effects are expected but take time 
to develop. In an evaluation of the PCV-vaccine from British Columbia, Canada, 7 years after 
vaccine start IPD decreased with 78 % among children < 5 (31). Interestingly, among the 
population aged 16 years and above, there were also clear evidence of herd immunity (31).  
Over all, to make a more precise prognosis of vaccine effect, knowledge about serotype 
distribution among disease-causing pneumococci in the area is needed. The pneumococcal 
bacteria exist in more than 90 different serotypes and serotype coverage for the PCV-13 
vaccine differs between countries as the pneumococcal serotype distribution varies. In the 
Pneumococcal global serotype project, Johnson et.al analyzed a large number of studies from 
13 of Africa’s countries. In Africa as a whole, the data analysis declared mean average 
serotype coverage for the PCV-13 vaccine with 77% (22). However, it appears as if West 
Africa has a higher prevalence of non-vaccine serotype pneumococci. In a study from the 
West-African countries Burkina Faso and Togo, Traore Y. et al. found that serotype coverage 
was just 62%(32). Possibly, Cameroon has a high prevalence of non-vaccine serotypes? 
As a result of vaccine routines, we predicted a higher vaccine rate for children aged 1-24 
month and a declince in number of cases after vaccine introduction. However, the number of 
pneumonia cases in Buea and Limbe rose from 101 to 114 in the 1-24 months age group after 
vaccine introduction. These results are the direct opposite to what we had expected and the 
findings are difficult to explain.  
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Unfortunately, there was no information about IPD as blood cultures were not performed in 
Buea or Limbe regional hospital. As a consequence, we don´t know the proportion of invasive 
disease that is caused by pneumococci.  
Several diseases as severe malaria, sepsis, meningitis etc. had defined diagnostic criteria 
posted on the walls of the pediatric unit and/or in the emergency ward or in the outpatient 
unit. However, there were no written diagnostic criteria for pneumonia in Buea or Limbe. The 
doctors in Buea and Limbe defined pneumonia as how they had learned in medical school. 
The definition differed somewhat between doctors, with different focus on auscultation, rate 
of chest x-rays etc. Although a mutual finding was that respiratory rate was not measured and 
calculated on a regular basis.  
There were more boys than girls affected with pneumonia, both before and after vaccine 
introduction. It is known from other diploma studies from the Sahlgrenska Academy and 
Denmark among others that boys are treated for pneumonia more frequently than girls (33-
35). It remains unclear if this is due to physiological disadvantages or if girls are being taken 
to hospital to a lesser extent. However, when in hospital, girls were diagnosed with severe 
pneumonia to a higher extent than boys. What this stands for remains unclear. One hypothesis 
is that girls are being taken to the hospital in a later stage of the disease and as a consequence 
develop more severe forms of pneumonia before initiating treatment.  
The low HIV-figures are probably an underestimation. Supposedly some of the patients may 
have had HIV that wasn´t being noted in the ledger. Possibly, it could be that parents of HIV-
infected children did not inform the medical staff about the underlying illness, or that the 
children might have been treated elsewhere, for example at the HIV-/AIDS-unit. 
Previous studies have shown that a drop in temperature to a certain level may increase the 
number of pneumonia cases (36). In a large population-based study from Taiwan with a study 
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sample of more than 477.000 pneumonia cases, there was a clear correlation between 
temperature and number of pneumonia cases(36). A drop in temperature implied an increase 
in number of pneumonia cases. Interestingly, there was also a correlation with rainfall. 
Similar to our findings, with higher precipitation, there was a decline in number of pneumonia 
cases. In Buea and Limbe, the climate is temperate and varies only a few degrees Celsius over 
the year in contrast with the average rainfall that varies substantially. Hence, the small drop in 
temperature during the wet season in Buea and Limbe is probably not the reason for the 
absence of pneumonia cases. The negative correlation between rainfall and pneumonia 
incidence in this study remains as an interesting finding. Could rainfall or humidity play a role 
in pneumonia incidence? More studies are needed to test this hypothesis. 
A problem with today’s vaccines is that they are not thermo stable. For example the PCV-13 
vaccine has to be stored between 2-8 degrees Celsius. This demands a stable cold chain 
system and appropriate equipment. Health care centers and hospitals thus need 
refrigerators/freezers, educated personal and alternative sources of power to avoid power 
interruption. Infrastructure such as good roads is also essential in order to deliver vaccines to 
health centers throughout the country. Low vaccine coverage in some regions of Cameroon is 
partly explained by bad roads, poor cold chain equipment and power interruption(4, 37).  
There was an underuse of oxygen therapy compared to treatment guidelines. There was an 
overuse of broad spectrum antibiotics compared to the written guidelines. Almost half of the 
cases were treated with Gentamycin as combination therapy, despite the fact that Gentamycin 
is not mentioned in the treatment guidelines. It would of course be ideal to do blood cultures 
and streamline the prescription of antibiotics. Though, it is understandable that physicians 
sometimes need to prescribe broad spectrum antibiotics as no blood cultures were being made 
on a regular basis at the hospitals; and as blood cultures are expensive and might not be the 
first matter to prioritize when money is scarce.  
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Limitations 
For the time of this study, the one pediatrician at the Buea Regional Hospital, where the 
bigger part of the study was conducted, was unfortunately on leave. The department was then 
run by two general practioners taking turns every second week. Useful information from an 
experienced specialist might have gone missing that way.  
There was no way to find out if the individual cases included in the study had been 
vaccinated. No information about vaccination status was kept in the medical records. In 
general, the medical records did not comprise summaries or profound information about the 
patients.  
To be able to investigate gender differences, knowing gender was highly important to us. 
Hence, we had to exclude four of the cases with no information about gender.   
The study period stretched over 53 months with a breakpoint in the middle. It was divided 
into two periods 26.5 months long. This was the easiest way to compare the two periods with 
each other. Though, the periods have different start and end months. That means that the 
“before” period in total have one more month of wet season compared to the dry season. This 
could play a marginal role when comparing the “before” and “after” periods.    
The medical files stored in the Limbe Regional Hospital archive seemed to comprise slightly 
more detailed information compared to the medical records in Buea Regional Hospital. It 
would have been of interest going through all of the medical files in Limbe for additional 
information regarding symptoms and treatment of the in-patients in Limbe. However, within 
the time frame of this master thesis and the limited amount of time left after collecting data in 
Buea Regional Hospital, this was not possible. 
26 
 
Some of the strengths of the study were that the admission book in both hospitals, but 
especially in Buea, comprised brief but seemingly accurate information. The total number of 
cases collected was also high regarding the short period of time that the study was conducted.  
 
Conclusions 
 Despite the negative results, it is too early to conclude that the PCV-13-vaccine will 
not have any effect on pneumonia incidence among children in the region. A longer 
follow up time, and more studies and larger numbers are necessary.  
 To make a more precise prognosis of vaccine effect, knowledge about serotype distribution 
both among disease-causing and carriage isolates of pneumococci in the area is needed. 
 
Implications 
 Use oxygen treatment more frequently. If possible, streamline the use of antibiotics. 
 Implement common written diagnostic guidelines for pneumonia in the emergency 
ward, pediatrics, out-patient department etc for optimizing treatment. Measure 
respiratory rate on a regular basis. 
 If vaccination status of individual children would have been known and registered in 
the medical records it would have been much easier to evaluate vaccine effect. 
 
 
 
.  
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Populärvetenskaplig sammanfattning 
Lunginflammation orsakar varje år 1.3 miljoner dödsfall bland barn under 5 år världen över. 
Det är fler än AIDS, tuberkulos och malaria sammantaget. Majoriteten av dessa inträffar i 
Afrika söder om Sahara och i södra Asien. I Kamerun är lunginflammation den näst 
vanligaste dödsorsaken (efter malaria) bland barn under 5 år och orsakar 18 % av alla 
dödsfall. Lunginflammation botas relativt enkelt med antibiotika, och kan effektivt 
förebyggas med förbättrad levnadsstandard och bättre luftförhållanden samt genom 
vaccinering. Enligt WHO är vaccinering det mest effektiva sättet att förebygga insjuknande i 
lunginflammation.  
Lunginflammation kan orsakas av bakterier, virus såväl som svampar. Den vanligaste orsaken 
är infektion med bakterien Streptococcus pneumoniae. I juli 2011 infördes ett 13-valent 
konjugatvaccin (PCV-13) mot pneumokocker i Kamerun. Inga utvärderande studier av 
vaccinets effekt har hittills gjorts i Kamerun.  
Vi gick igenom alla fall av lunginflammation för barn i åldern 1 månad till 5 år som vårdats 
på Buea- samt Limbe Regional Hospital någon gång sedan juni 2009. Antalet fall i 
lunginflammation, allvarlighetsgrad- samt dödlighet i sjukdomen studerades före och efter 
vaccinstart. Även val av behandling undersöktes.  
Det gick inte att se några tidiga effekter av vaccinet. Varken på antal fall av 
lunginflammation, allvarlighetsgrad eller dödlighet. En minskning från 137 fall till 136 fall 
perioden efter vaccinets införande noterades. Andelen allvarliga lunginflammationer ökade 
något efter vaccinstart. Antalet dödsfall till följd av sjukdomen var 2 före vaccinets införande 
respektive 6 perioden efter vaccinstart. Vi studerade även den yngsta delen av populationen 
(1-24 månader) där andel vaccinerade rimligvis borde vara som högst, men inte heller där 
syntes några positiva effekter av vaccinet. Tvärtom ökade antalet fall från 101 till 114 i yngsta 
gruppen. Dock är inga av ovanstående resultat statistiskt säkerställda.  
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Det fanns en tydlig säsongsvariation med färre fall av lunginflammation under regnperioden 
och fler fall under torrperioden. Detta samband har även setts i andra studier men orsakerna 
till detta är fortsatt ej klarlagda.  
Flera studier har visat på god effekt av PCV-vacciner. Varför ingen effekt påvisats i denna 
studie är öppet för diskussion. Det tar tid att uppnå allmänna mätbara effekter av vaccinering 
och möjligen var den studerade tidsperioden efter vaccinstart för kort? Eventuellt finns det i 
Kamerun, en hög andel varianter av bakterien Streptococcus pneumoniae som inte täcks av 
PCV-13 vaccinet? Kanske har andra faktorer såsom nederbörd eller luftfuktighet inverkan på 
förekomst av lunginflammation?  
Det är dock för tidigt att säga att PCV-13-vaccinet inte har några effekter för barn under 5 års 
ålder i Kamerun. Fler, större och fördjupade studier på området behövs för att vidare 
undersöka vaccinets effektivitet. Framtida studier behövs även för att undersöka ett eventuellt 
samband mellan pneumoni och nederbörd.  
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